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to investigate mechanisms of action, develop new therapies, and evaluate efficacy of adoptive transfer.
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Introduction
This review focuses on current methods to track natural killer 
(NK) cells used in cancer therapy: how they can be monitored 
in vivo to assess tumor response, assay treatment efficacy, and 
elucidate mechanisms of NK cell-based immunotherapy. NK 
cell therapy includes activation of endogenous NK cells, and 
adoptive transfer of activated and genetically modified NK cells. 
Adoptive transfer of ex vivo-targeted NK cells has been used 
more recently. Typically, response to adoptive cell therapy is 
evaluated on the basis of decreases in tumor markers and tumor 
size and improved survival that are assessed weeks to months 
after administration of treatment. Localization and func-
tion of adoptively transferred immune cells at the tumor site 
are typically determined through biopsy and ex vivo analysis. 
Accumulation in the tumor region is one of the requirements 
for effective adoptive immunotherapy. With the biology of NK 
cells continually being elucidated, tumor  targeting of NK cells 
can potentially be enhanced using a variety of new methods.
NK cells may be labeled with different markers for in vivo 
monitoring.1 Cells can be labeled directly by harvesting them 
and labeling them ex vivo with fluorophores, radiotracers, or 
paramagnetic nanoparticles that allow visualization by opti-
cal microscopy, positron emission tomography/single-photon 
emission computed tomography (PET/SPECT), and mag-
netic resonance imaging (MRI), respectively. Direct  label-
ing procedures may prove to be useful for clinical translation 
because of the ease of labeling procedures and the potential 
to use labels that are already approved for clinical use. This 
method, however, has two disadvantages. First, the level 
of labeling depends on the capacity of the cell to retain the 
label, as different cell populations may exhibit different lev-
els of phagocytosis or have different membrane properties. 
Second, the direct method can be useful for in vivo imag-
ing of only terminally differentiated cells, such as NK cells, 
dendritic cells, and macrophages, because the label may be 
lost or diluted as cells proliferate or die. Cells may also be 
labeled indirectly ex vivo where cells are transduced with a 
vector carrying a reporter gene. Signal can be generated and 
tracked in vivo when the reporter gene is expressed and when 
a transgene-specific probe is administered. Although genetic 
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manipulation makes it possible to track the long-term fate of 
a cell population (distribution, proliferation, and survival) in 
vivo, insertion of reporter genes demands stable genetic modi-
fication and is currently restricted to preclinical research.
Noninvasive imaging technologies are now able to quali-
tatively and quantitatively detect the presence of labeled NK 
cells in target tumors. These imaging signals can potentially 
be used as real-time biomarkers for tumor response and for 
differentiating patients who are responders or nonresponders 
to NK cell therapy. Noninvasive NK cell imaging has the 
potential to provide immediate evaluation of NK cell therapy 
in both preclinical and clinical realms.
NK Cells
NK cells are a crucial part of the innate immune system that 
were originally identified based on their ability to lyse malig-
nant and infected cells without prior sensitization or immu-
nization.2 NK cells mediate the suppression of infected and 
tumor cells through several effector mechanisms (e.g. the 
perforin/granzyme-containing granule, death-receptor and 
interferon-γ (IFN-γ) mediated pathways, and antibody-
dependent cell-mediated cytotoxicity (ADCC)).3 NK cells 
produce cytokines that have proinflammatory and immu-
nosuppressive effects (e.g. IFN-γ, tumor necrosis factor-α 
(TNF-α), or interleukin IL-10) and growth factors, such as 
granulocyte macrophage colony-stimulating factor (GM-
CSF) and granulocyte colony-stimulating factor (G-CSF)). 
They also produce many kinds of chemokines that are crucial 
in NK cell trafficking to lymph nodes and areas of inflamma-
tion, as well as their colocalization with dendritic and other 
hematopoietic cells.4,5 NK cell-mediated cytotoxicity and 
cytokine production provide regulatory roles of NK cells that 
impact members of the adaptive immune system, such as den-
dritic cells, macrophages, neutrophils, and T and B cells.4
Human NK cells are broadly defined as CD3- CD56+ 
cells and can be further divided into two subsets based on the 
level of their expression of CD56.6 CD56bright NK cells are 
predominantly involved in immunoregulation by producing 
cytokines. CD56dim NK cells are mainly cytolytic. CD56dim 
NK cells also express high levels of low-affinity Fc receptor 
for IgG (FcγIIIR—CD16), which mediates ADCC. NK cells 
are widely distributed throughout lymphoid and nonlymphoid 
tissues, including bone marrow, lymph nodes, blood, liver, 
spleen, and lung.5 About 90% of NK cells in the peripheral 
blood and spleen are CD56dim CD16+ NK cells. Most NK 
cells in the lymph nodes are CD56brightCD16dim/-.7
NK cells are equipped with a variety of receptors that 
stimulate or inhibit activity. NK cell activation is dependent on 
the balance between inhibitory and activating receptors. Acti-
vating receptors interact with soluble ligands like  cytokines 
and cell surface antigens. Human activating receptors include 
the natural cytotoxicity receptors (NCR–NKp46, NKp30, 
and NKp44), C-type lectin receptors (CD94/NKG2C, 
NKG2D, NKG2E/H, and NKG2F), and killer cell immu-
noglobulin-like receptors (KIRs) (KIR-2DS and KIR-3DS). 
Inhibitory receptors include C-type lectin receptors (CD94/
NKG2A/B) and KIRs (KIR-2DL and KIR-3DL).8 The NK 
cell receptor repertoire provides three ways by which NK 
cells take part in tumor immune surveillance. First is the 
“missing self-recognition” mechanism. At steady state, nor-
mal cells express major histocompatibility complex (MHC) 
class I “self ” molecules that bind to inhibitory receptors and 
inhibit NK cell killing. Under stress conditions, MHC class I 
is down- regulated in target cells resulting in loss of inhibitory 
signals and activation of NK cells. Second is the “non-self 
recognition” process. NK cells possess activating receptors 
that recognize molecules that are pathogen-encoded, only 
expressed by infected cells, and are not expressed by the 
host. For example, in mice, the cytomegalovirus-encoded 
m157 ligand is recognized by the activating receptor Ly49H 
in NK cells. Human NK cell activating receptor NKp46 can 
recognize hemagglutinins on virus-infected cells and initiate 
NK cell-mediated lysis.9–13 Third is the “stress-induced self ” 
process, wherein NK cells recognize proteins up-regulated 
only by transformed or infected cells. Furthermore, IFNs 
and cytokines (IL-2, IL-12, IL-15, IL-18, and IL-21) can 
potentiate these surveillance roles by enhancing activation, 
increasing cytolytic activity and promoting maturation of 
NK cells.4,8
NK Cells in Tumor Immunotherapy
NK cells play crucial roles in the innate and adaptive immu-
nities against infections and tumors. Their therapeutic use is 
currently being pursued in cancer immunotherapy.8,14 Briefly, 
there are five methods in which NK cell therapy is being 
employed pre-clinically and clinically.
(1) Autologous NK cells can be activated and potentiated 
through systemic administration of cytokines (IL-2, IL-12, 
IL-15, IL-18, IL-21, and type I IFNs).4,15–18 However, poor 
clinical outcome has been observed with severe side effect in 
cancer patients, including vascular leak. Ex vivo activation 
and expansion of autologous NK cell using cytokines and 
eventual adoptive transfer back to the patients have shown 
greater success.8
(2) Use of allogeneic NK cells in adoptive cell transfer 
has shown KIR mismatch and enhanced tumor-killing abil-
ity. KIR mismatch contributes to alloreactivity of NK cells 
through the “missing self-recognition” process, i.e. the inhibi-
tory KIRs on allogeneic NK cells do not detect self MHC 
class I ligands.19,20 Following transfer of haploidentical alloge-
neic NK cells in acute myeloid leukemia (AML) patients, 26% 
had complete remission and most patients experienced NK cell 
expansion following IL-2 therapy.19 To take advantage of the 
alloreactivity of NK cells, they are expanded and activated in 
vitro prior to adoptive transfer using various cytokines (IL-2, 
IL-15, or IL-21) and growth factors.21,22 NK cell function can 
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also be enhanced by blocking inhibitory KIR with monoclo-
nal antibodies.23
(3) ADCC: NK cells expressing the activating receptor 
type IIIA Fc receptor (CD16) recognize antibodies on target 
cells and trigger NK cell-mediated ADCC. The use of mono-
clonal antibodies with or without immunocytokine stimu-
lation of endogenous or adoptive NK cells could potentiate 
ADCC and improve immunotherapy. Antibody treatment of 
non-Hodgkin lymphoma (with anti-CD20—Rituximab) and 
metastatic breast cancer (with anti-transtuzumab/Herceptin) 
shows strong evidence that ADCC is NK cell mediated.24–26
(4) NK cell lines: Ex vivo-activated NK cells have 
increased cytolytic activity compared to parental NK cells. 
This has led to the use of cytotoxic NK cells lines that can 
be continuously expanded, maintained using good manufac-
turing practice (GMP), and kept readily available without a 
donor. There are seven established NK cells lines: NK-92, 
YT, NKL, HANK-1, KHYG-1, NK-YS, and NKG.8,27 The 
human NK-92 cell line originated from a patient with large 
granular lymphoma and is the only cell line that has been 
shown safe in adoptive transfer in humans.28,29 NK-92 cells 
can also be expanded in recombinant IL-2. More recently, 
Tonn et al showed that infusions of ex vivo IL-2-activated 
NK-92 cells were well tolerated in patients with advanced 
cancer and remain in circulation up to 48 hours.30
(5) Genetic modification: In addition to mediating cyto-
toxicity of NK cells, it is also important to optimize accumula-
tion and retention of the modified NK cells at the tumor site by 
altering the targeting receptor milieu. Small interfering RNA 
(siRNA)-based technologies can be used to down-regulate 
the expression of inhibitory NK cell receptors or overexpress 
activating receptors.31–33 Gene transfer of chimeric tumor-
antigen-specific receptors in NK cells enhance their tumor 
targeting and killing abilities. Studies in vitro and in vivo have 
shown that genetic modification of NK cells via transfer of 
chimeric receptors targeted against HER2/neu, carcinoem-
bryonic antigen (CEA), CD33+ leukemia, and epithelial cell 
adhesion molecules (EpCAM)-positive prostate cancer pro-
vided specific cytotoxicity.34–39 Genetically modifying NK-92 
cells with CD20-specific chimeric antigen potentiated NK 
cell cytotoxicity toward a CD20 expressing lymphoma that 
was previously resistant to NK cells.40
Multimodal immunotherapy promises to optimize NK 
cell efficacy and tumor targeting.15 NK cell therapy can be 
combined with cytokines, hematopoietic growth factors, 
humanized monoclonal antibodies, immunocytokines, and/
or immunomodulatory drugs.4,15–18,41,42 Other types of cancer 
treatments may provide some tumor priming that could also 
enhance direct or indirect NK cell-mediated tumor recogni-
tion and killing. Ionizing radiation and chemotherapy may lead 
to increased expression of NKG2D ligands on tumor cells and 
increased NK cell targeting and binding of NKG2D  activating 
NK cell receptors.43 Drugs acting on histone deacetylase 
inhibitors or proteasome inhibitors may up- regulate  expression 
of TNF-related apoptosis-inducing ligands on malignant 
cells and render them more susceptible for TRAIL-mediated 
NK cell-induced death.44–47 Focused ultrasound treatment of 
human breast cancer increases tumor-infiltrating lymphocytes 
that include: CD3, CD4, CD8, CD4/CD8 T cells, B cells, 
and NK cells. Levels of FasL+, granzyme+, and perforin+ 
lymphocytes also significantly increase after focused ultra-
sound treatment.48 Focused ultrasound has also been used 
to disrupt the blood-brain barrier to deliver targeted NK-92 
cells expressing a chimeric HER2 antigen receptor to HER2-
expressing human breast tumor cells.49
Current NK Cell Tracking Methods
Quantitation of the distribution and timing of NK cell traffick-
ing is necessary to clinically assess the efficacy of their adoptive 
transfer. Using various imaging techniques, this evaluation can 
be done quickly and noninvasively in patients receiving adop-
tive NK cell therapy. There are currently three methods to track 
NK cells in vivo50: (1) optical imaging (OI) using fluorescence 
(FLI) or bioluminescent imaging (BLI), (2) radionuclide-based 
imaging using PET or SPECT, and (3) MRI.
Direct or indirect cell labeling can be used to track NK 
cells using OI. Cells can be directly labeled with exogenous 
fluorescent tracers for FLI or indirectly via transfection 
of a reporter gene that generates a protein product for FLI 
(e.g. green fluorescent protein, GFP) or BLI (e.g. luciferase). 
Fluorescent dyes can be used to permanently label NK cells and 
other lymphocytes through covalent and noncovalent binding 
to DNA, RNA, and protein sites; cell membrane insertion; 
and reactions in the cytosol.51 Optical markers exhibit high 
sensitivity and high specificity, but provide limited resolution 
(2–3  mm), poor anatomical discrimination, and limited tis-
sue penetration (1 mm fluorescence; 3 mm bioluminescence). 
OI is well suited for small animal models due to small tis-
sue depths as compared to humans. There are also no readily 
available clinical instruments.
Using OI, NK-92scFv(MOC31)-zeta cells targeted to 
EpCAM antigen in human prostate cancer xenografts have 
been tracked in vivo in athymic rats using a near-infrared dye 
DiD (1,1′-diotadecyl-3,3,3′,3′-tetramethylindodicarbocyanine). 
Tumor fluorescence increased significantly after injection of 
targeted NK-92 cells vs. nontargeted parental NK-92 cells 
(Fig. 1).39 NK-92MI cells have also been labeled with anti-
CD56 antibody conjugated with quantum dots (QD705) 
without affecting viability and IFG-γ production and cyto-
lytic activity. QD705-labeled NK cells have been tracked up 
to 12  days post intratumoral injection in human malignant 
melanoma (MeWo) xenografts in mice.52 Conjugation of 
fluorescence organic dye (Cy5.5) with magnetic nanoparticles 
(Fe3O4/SiO2) has also been used to visualize the migration 
of NK-92MI cells to the tumor site controlled by an external 
magnetic field.53
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PET and SPECT provide high sensitivity for detect-
ing labeled NK cells (in the nanomolar concentration range), 
high specificity (target to background contrast), quantifica-
tion of labeled cells, and has immediate clinical translation 
through use of FDA-approved labeling agents. However, 
limitations include poor spatial resolution (~1–5 mm), limited 
anatomic information, ionizing radiation, and, depending on 
the radionuclide, limited duration and number of scanning 
sessions.50 Radionuclide tracer decay limits follow-up stud-
ies within hours (18FDG 2–4 hours) to days (111In 4–7 days). 
Integration of computed tomography (CT) can improve the 
resolution of PET and SPECT through attenuation correc-
tion and allows registration of tracer signals with anatomical 
structures.54
NK cells have been labeled with positron emitting 
radionuclides, including 18FDG (half life = 109  min) and 
11C-methyl iodide (half life = 20 min) for PET,22,35,55 as well as 
with gamma emitting radioisotope 111In (half life = 2.8 days) 
for SPECT.56,57 PET tracers have been used to experimentally 
investigate the optimization of NK cell targeting to tumors. 
Melder et al, using 11C-methyl iodide and PET, demonstrated 
that 4–30% of injected activated NK cells localized (1 hour 
post injection) to the tumor site of a murine FSaII fibrosar-
coma model compared to 3–4% of nonactivated splenic lym-
phocytes.22 Using an FDA-approved PET label, 18FDG, 
Meier et al tracked genetically modified NK-92 cells, NK-
92-scFv(FRP5)-zeta cells. These cells express a chimeric 
antigen receptor  targeting tumor-associated Her2/Neu anti-
gens, and were shown to accumulate more in the tumor site 
compared to parental NK-92 cells in mice (Fig. 2).35 Addi-
tionally, SPECT agents have been used to explore optimal 
 administration routes for adoptively transferred NK cells 
clinically. Matera and colleagues used 111In-oxide-labeled 
recombinant IL-2-activated NK cells, evaluated by SPECT, 
to show that intra-arterial injection vs. intra-venous results in 
increased accumulation of adoptively transferred NK cells in 
the liver tumor site (colon carcinoma metastasis).56
For MRI, NK cells have been labeled with nanoparticles, 
such as superparamagnetic iron oxide (SPIO) and ultra-small 
superparamagnetic iron oxide (USPIO) nanoparticles.34,36,58,59 
Depending on how long the adoptively transferred NK cells 
survives; NK cells are able to retain their iron oxide label up to 
4 days.58 Iron oxide-based agents produce strong hypointen-
sity in T2 and T2* weighted images. Interpretation of the signal 
loss may be difficult because other factors could contribute to 
the hypointensity regions in an image, apart from the pres-
ence of iron oxide-labeled cells (e.g. presence of blood, sus-
ceptibility artifacts due to air–tissue interfaces, magnetic field 
inhomogeneities due to poor shimming, etc.). Even with its 
drawbacks, direct labeling with paramagnetic particles show 
promise of direct clinical translation since FDA-approved iron 
oxide nanoparticles are already in clinical use (ferumoxide, 
ferumoxytol, and ferucarbotran) and iron oxide nanoparticle 
labeling involves simple incubation, electroporation, or use of 
a transfection agent.34 Direct measurement of the relaxation 
rate, R2* (R2* = 1/T 2*) provides quantification of the attenu-
ated signal intensity. R2* relaxometry displays the effects of 
iron oxide as a positive signal and is a quantitative measure 
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Figure 1. Adapted from Tavri et al,39 with permission. Optical (fluorescence) imaging scans of rats with EpCAM-positive DU145 prostate cancer 
xenografts (arrow) before and after injection of targeted (NK-92-scFv(MOC31)-zeta) (subject #4) and nontargeted NK-92 cells (subject #7) labeled with 
DiD. Scans show increases in tumor fluorescence signal at 1.5–24 hours post injection (p.i.) of NK cells. The subject that received nontargeted NK-92 
cells shows nonspecific signal in the liver/lung region 1.5–24 hours p.i. The subject that received the targeted NK-92 cells showed the nonspecific liver/
lung fluorescence only at 8 hours p.i.
In vivo monitoring of NK cell trafficking during tumor immunotherapy
19Magnetic Resonance insights 2014:7
that correlates with iron concentration. Use of ultra short 
echo-time (UTE) pulse sequence60 is an alternative imaging 
protocol that can display signal increase in the presence of iron 
oxide nanoparticles.
Meier et al demonstrated significant decreases in 
T2*-weighted signals in EpCAM-positive tumors after 
injection of ferumoxide-labeled EpCAM-targeted NK-92 
cells (NK-92-scFv(MOC31)-zeta), but not after injection 
of  ferumoxide-labeled nontargeted parental NK-92 cells 
(Fig. 3).36 For a more quantitative approach, relaxation rate 
maps can be constructed to provide quantitative metrics of 
the organ and tumor tissues and possibly labeled NK cell 
concentrations. For instance, Sheu et al showed that tumor 
signal changes in T2* relaxation time maps generated from 
gradient echo sequences after intra-arterial infusion of 
SPIO-labeled NK-92 cells.59 Figure 4 shows a T2*-weighted 
image and the  corresponding parametric R2* (R2* =  1/T2*) 
map of an NOD-scid-gammanull (NSG) mouse implanted 
with Daudi Burkitt’s  lymphoma before (pre) and after 
(6 hour post) tail vein injection of ferumoxtyol-labeled NK 
cells. The R2* maps show a heterogeneous signal increase in 
the tumor region 6  hour after administration of ferumox-
tyol-labeled NK cells.
MRI is readily available clinically, has relatively high 
resolution (better than 0.1 mm), well-defined soft-tissue con-
trast, and has no ionizing radiation. Disadvantages of MRI 
compared to OI or radiotracer-based imaging are limited 
sensitivity for detecting small cell populations, relatively high 
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Figure 2. Reprinted with permission from Meier et al.35 (Left) Representative digital autoradiographs of tumors and organ tissues from mice with HER2/
neu-positive sarcoma that received 18FDG-labeled targeted NK-92 (NK-92-scFv(FRP5)-zeta) cells (A) and nontargeted parental NK-92 cells (B). The 
signal intensity bar shows count density of photostimulated luminescence per unit area: PSL/mm2 (in log scale). (Right) Uptake of radioactivity in selected 
organs subtracted from the background noise (rectangular box on autoradiograph image).
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Figure 3. Reproduced with permission from Meier et al.36 Axial and coronal T2*-weighted gradient echo images (TR/TE = 5.1/500 ms) of representative 
EpCAM-positive DU154 tumors (arrows) before and after injection of ferumoxide-labled targeted NK-92 (NK-92-scFv(MOC31)-zeta) and nontargeted 
parental NK-92 cells. There is a signal decrease at the tumor site at 1 hour and 24 hours post injection only after administration of ferumoxide-labeled 
NK-92-scFv(MOC31)-zeta cells.
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cost, long scan times, and low specificity. Quantitation of cells 
in vivo is theoretically possible using relaxation rate maps, 
but this type of quantification is indirect as the MR signal 
detected is related to the perturbation in tissue proton magne-
tization rather than directly to cell concentration.
Conclusion
Autologous NK cell or NK cell lines are being used clinically. 
Multiplexing adoptive transfer with patient and tumor prim-
ing (via adjuvant and/or immunocytokine treatments, genetic 
modification of NK cells, and/or combinatorial therapies) are 
being explored to optimize targeting to the tumor and enhance 
cytotoxicity of NK cells. In vivo assessment of the spatiotem-
poral distribution and the concentration of transferred NK 
cells within tumor sites are necessary to evaluate the efficacy 
of NK cell-based therapies in patients. Existing imaging tech-
niques with optimized probes can be used noninvasively and 
results can be visualized in real time. For future clinical appli-
cations, multimodal imaging (MRI and PET) offers the most 
desirable characteristics for measuring responses to NK cell 
adoptive therapy, to qualitatively and quantitatively track 
cells, and to measure cellular viability through visualization of 
PET and MRI signal colocalization.
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